A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma

Academic Article

Abstract

  • Both the amplification of the gene coding for wild-type (wt) epidermal growth factor receptor (EGFR) and the overexpression of the EGFR deletion mutant, commonly known as EGFRvIII, are hallmarks of glioblastoma. We have recently reported a novel, recombinant immunotoxin, D2C7-(scdsFv)-PE38KDEL, that targets both wt EGFR and EGFRvIII, exhibiting potent antineoplastic effects against established murine gliomas. © 2013 Landes Bioscience.
  • Authors

    Digital Object Identifier (doi)

    Author List

  • Chandramohan V; Bigner DD
  • Start Page

  • 1
  • End Page

  • 2
  • Volume

  • 2
  • Issue

  • 12